These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 36814159)

  • 21. Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study.
    Warkentin L; Werner F; Zeschick N; Kühlein T; Steininger P; Überla K; Kaiser I; Sebastião M; Hueber S
    BMC Med; 2023 Jun; 21(1):218. PubMed ID: 37340463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Raethke M; van Hunsel F; Thurin NH; Dureau-Pournin C; Mentzer D; Kovačić B; Mirošević Skvrce N; De Clercq E; Sabbe M; Trifirò G; Luxi N; Giovanazzi A; Shakir S; Klungel OH; Schmikli S; Sturkenboom M
    Drug Saf; 2023 Apr; 46(4):391-404. PubMed ID: 37024736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
    Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
    J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system.
    Enayatrad M; Mahdavi S; Aliyari R; Sahab-Negah S; Nili S; Fereidouni M; Mangolian Shahrbabaki P; Ansari-Moghaddam A; Heidarzadeh A; Shahraki-Sanavi F; Fateh M; Khajeha H; Emamian Z; Behmanesh E; Sheibani H; Abbaszadeh M; Jafari R; Valikhani M; Binesh E; Vahedi H; Chaman R; Sharifi H; Emamian MH
    BMC Infect Dis; 2023 Mar; 23(1):150. PubMed ID: 36899326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
    Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Vichaiwattana P; Thongmee T; Auphimai C; Srimuan D; Thatsanatorn T; Assawakosri S; Kanokudom S; Poovorawan Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):2029111. PubMed ID: 35209809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
    Bosaeed M; Balkhy HH; Almaziad S; Aljami HA; Alhatmi H; Alanazi H; Alahmadi M; Jawhary A; Alenazi MW; Almasoud A; Alanazi R; Bittaye M; Aboagye J; Albaalharith N; Batawi S; Folegatti P; Ramos Lopez F; Ewer K; Almoaikel K; Aljeraisy M; Alothman A; Gilbert SC; Khalaf Alharbi N
    Lancet Microbe; 2022 Jan; 3(1):e11-e20. PubMed ID: 34751259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term COVID-19 vaccine adverse effects among adults in Ekiti State, Nigeria.
    Dele-Ojo BF; Adesokan A; Fadare JO; Ajayi PO; Raimi TH; Dada SA; Ojo OD; Ogunmodede JA; Ipinnimo TM; Ariyo OE; Godman B
    Curr Med Res Opin; 2024 Apr; 40(4):621-627. PubMed ID: 38323854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse effects following COVID-19 vaccination in Iran.
    Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
    BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 vaccination during pregnancy: coverage and safety.
    Blakeway H; Prasad S; Kalafat E; Heath PT; Ladhani SN; Le Doare K; Magee LA; O'Brien P; Rezvani A; von Dadelszen P; Khalil A
    Am J Obstet Gynecol; 2022 Feb; 226(2):236.e1-236.e14. PubMed ID: 34389291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse Events Following the First Dose of Immunization of COVID-19 Vaccine.
    Bhandari B; Jha N; Khan IH; Rayamajhi G; Thapa L; Bista B
    J Nepal Health Res Counc; 2022 Jun; 20(1):59-64. PubMed ID: 35945854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
    Cohen G; Jungsomsri P; Sangwongwanich J; Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052525. PubMed ID: 35323079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
    Rosenblum HG; Gee J; Liu R; Marquez PL; Zhang B; Strid P; Abara WE; McNeil MM; Myers TR; Hause AM; Su JR; Markowitz LE; Shimabukuro TT; Shay DK
    Lancet Infect Dis; 2022 Jun; 22(6):802-812. PubMed ID: 35271805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.